{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:52:47Z","timestamp":1790110367048,"version":"4.0.1"},"reference-count":261,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:00:00Z","timestamp":1778544000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Gastric cancer (GC) ranks as the third leading cause of cancer-related mortality worldwide, and its management remains formidable. Immunotherapy has been highly praised for its remarkable efficacy and acceptable toxicity, and its development has outpaced that of traditional therapies. However, molecular heterogeneity and the immunosuppressive tumor immune microenvironment (TIME) have hindered the treatment response of a considerable number of patients. This review synthesizes the latest therapeutic advances, spanning immune-checkpoint inhibitors (ICIs), adoptive cell therapy (ACT), monoclonal antibodies and antibody drug conjugates (ADCs), cancer vaccines, tumor-infiltrating lymphocyte (TIL) therapy, and CAR-T cells therapy. Emerging strategies such as RNA interference nano-delivery systems, immune adjuvants, and microbiota modulation are constantly evolving to transform \u201ccold\u201d tumors into \u201chot\u201d tumors. Persistent challenges include primary resistance, immune-related adverse events (irAEs) and antigenic heterogeneity, underscoring the imperative for refined patient stratification. Classical biomarkers such as PD-L1 expression, tumor mutational burden (TMB), mismatch-repair status, Epstein\u2013Barr virus (EBV) positivity and circulating tumor DNA (ctDNA) all demonstrate predictive value but remain constrained by spatial heterogeneity and temporal dynamics. Consequently, we highlight emerging biomarkers that integrate metabolic, epigenetic and cell-death signatures, providing a roadmap for precision immunotherapy and continuous optimization of GC treatment algorithms.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1742723","type":"journal-article","created":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:43:59Z","timestamp":1778564639000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Unlocking the potential: current landscape and future directions of immunotherapy in gastric cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Yingfei","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Clinical Medicine, Qingdao University","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luling","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Qingdao University","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luoyang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Basic Medicine, Qingdao University","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Basic Medicine, Qingdao University","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Immunology, School of Basic Medicine, Qingdao University","place":["Qingdao, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061538","article-title":"In vivo and in vitro enhanced tumoricidal effects of metformin, active vitamin D(3), and 5-fluorouracil triple therapy against colon cancer by modulating the PI3K\/Akt\/PTEN\/mTOR network","volume":"14","author":"Almaimani","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21657","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s10020-025-01075-y","article-title":"Targeted therapy and immunotherapy for gastric cancer: rational strategies, novel advancements, challenges, and future perspectives","volume":"31","author":"Luo","year":"2025","journal-title":"Mol Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1212476","article-title":"Cancer immunotherapies: advances and bottlenecks","volume":"14","author":"Rui","year":"2023","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000002185","article-title":"Research progress in targeted therapy and immunotherapy for gastric cancer","volume":"135","author":"Li","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1177\/1747493018778713","article-title":"Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke","volume":"13","author":"Sacks","year":"2018","journal-title":"Int J Stroke: Off J Int Stroke Soc"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.56735","article-title":"Progress of gastric cancer surgery in the era of precision medicine","volume":"17","author":"Wang","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1038\/s41467-025-58553-4","article-title":"Gut commensal Bifidobacterium-derived extracellular vesicles modulate the therapeutic effects of anti-PD-1 in lung cancer","volume":"16","author":"Preet","year":"2025","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.03.008","article-title":"Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development","volume":"10","author":"Yasuda","year":"2024","journal-title":"Trends Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12935-025-03655-8","article-title":"A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies","volume":"25","author":"Panahizadeh","year":"2025","journal-title":"Cancer Cell Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242015321","article-title":"Predictive biomarkers for immunotherapy in gastric cancer: current status and emerging prospects","volume":"24","author":"Hou","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3322\/caac.21596","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2613.2001.00204.x","article-title":"Viral escape mechanisms--escapology taught by viruses","volume":"82","author":"Lucas","year":"2001","journal-title":"Int J Exp Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0488-6","article-title":"The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications","volume":"17","author":"Zhang","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.116030","article-title":"Effect of metabolic reprogramming on the immune microenvironment in gastric cancer","volume":"170","author":"Shang","year":"2024","journal-title":"Biomedicine Pharmacotherapy = Biomedecine Pharmacotherapie"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/biology12020218","article-title":"Targets of immune escape mechanisms in cancer: basis for development and evolution of cancer immune checkpoint inhibitors","volume":"12","author":"Dutta","year":"2023","journal-title":"Biology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23084147","article-title":"JAK-STAT1 signaling pathway is an early response to Helicobacter pylori infection and contributes to immune escape and gastric carcinogenesis","volume":"23","author":"Li","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1038\/s41467-022-28479-2","article-title":"EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.129.5.2293","article-title":"Tumor-specific antigen of murine T-lymphoma defined with monoclonal antibody","volume":"129","author":"Allison","year":"1982","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1126\/science.271.5256.1734","article-title":"Enhancement of antitumor immunity by CTLA-4 blockade","volume":"271","author":"Leach","year":"1996","journal-title":"Sci (New York NY)"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/471561a","article-title":"Melanoma drug wins US approval","volume":"471","author":"Ledford","year":"2011","journal-title":"Nature"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31827-5","article-title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Kang","year":"2017","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29030131","article-title":"Immunotherapy in gastric cancer","volume":"29","author":"H\u00f6gner","year":"2022","journal-title":"Curr Oncol (Toronto Ont)"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030560","article-title":"Therapeutic immunomodulation in gastric cancer","volume":"16","author":"Akkanapally","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13050357","article-title":"Gastric cancer, immunotherapy, and nutrition: the role of microbiota","volume":"13","author":"Raoul","year":"2024","journal-title":"Pathog (Basel Switzerland)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2017-0597","article-title":"Upper gastrointestinal Malignancies in 2017: current perspectives and future approaches","volume":"14","author":"Solomon","year":"2018","journal-title":"Future Oncol (London England)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i16.2452","article-title":"Updates on global epidemiology, risk and prognostic factors of gastric cancer","volume":"29","author":"Yang","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/s0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1186\/s12967-024-05503-1","article-title":"Mutual exclusivity and co-occurrence patterns of immune checkpoints indicate NKG2A relates to anti-PD-1 resistance in gastric cancer","volume":"22","author":"Li","year":"2024","journal-title":"J Transl Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1578","article-title":"Blockade of V-domain immunoglobulin suppressor of T-cell activation reprograms tumour-associated macrophages and improves efficacy of PD-1 inhibitor in gastric cancer","volume":"14","author":"Cao","year":"2024","journal-title":"Clin Transl Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03650-9","article-title":"Structural basis of omega-3 fatty acid transport across the blood-brain barrier","volume":"595","author":"Cater","year":"2021","journal-title":"Nature"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12476","article-title":"MFSD2A potentiates gastric cancer response to anti-PD-1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response","volume":"43","author":"Zhang","year":"2023","journal-title":"Cancer Commun (London England)"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34474","article-title":"Complement receptor C5aR1 blockade reprograms tumor-associated macrophages and synergizes with anti-PD-1 therapy in gastric cancer","volume":"153","author":"Zhang","year":"2023","journal-title":"Int J Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02336-5","article-title":"C-type lectin receptor Dectin-1 blockade on tumour-associated macrophages improves anti-PD-1 efficacy in gastric cancer","volume":"129","author":"Liu","year":"2023","journal-title":"Br J Cancer"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1327055","article-title":"Current therapies and progress in the treatment of advanced gastric cancer","volume":"14","author":"Li","year":"2024","journal-title":"Front Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13020-016-0114-9","article-title":"Anti-cancer effects of Gynostemma pentaphyllum (Thunb.) Makino (Jiaogulan)","volume":"11","author":"Li","year":"2016","journal-title":"Chin Med"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1243353","article-title":"Gypenoside induces apoptosis by inhibiting the PI3K\/AKT\/mTOR pathway and enhances T-cell antitumor immunity by inhibiting PD-L1 in gastric cancer","volume":"15","author":"Wu","year":"2024","journal-title":"Front Pharmacol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174365","article-title":"Modulation of the tumor microenvironment (TME) by melatonin","volume":"907","author":"Mu","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.mce.2023.111917","article-title":"Melatonin enhances anti-tumor immunity by targeting macrophages PD-L1 via exosomes derived from gastric cancer cells","author":"Wang","year":"2023","journal-title":"Mol Cell Endocrinol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1186\/s12943-023-01883-y","article-title":"Hsa_circ_0136666 stimulates gastric cancer progression and tumor immune escape by regulating the miR-375\/PRKDC axis and PD-L1 phosphorylation","volume":"22","author":"Miao","year":"2023","journal-title":"Mol Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13148-018-0501-4","article-title":"Retinoic acid-induced 2 (RAI2) is a novel tumor suppressor, and promoter region methylation of RAI2 is a poor prognostic marker in colorectal cancer","volume":"10","author":"Yan","year":"2018","journal-title":"Clin Epigenet"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.18632\/aging.205135","article-title":"RAI2 acts as a tumor suppressor with functional significance in gastric cancer","volume":"15","author":"Lou","year":"2023","journal-title":"Aging"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2021.06.014","article-title":"Ferroptosis in the tumor microenvironment: perspectives for immunotherapy","volume":"27","author":"Xu","year":"2021","journal-title":"Trends Mol Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.7150\/thno.86928","article-title":"Histone deacetylase-mediated tumor microenvironment characteristics and synergistic immunotherapy in gastric cancer","volume":"13","author":"Lin","year":"2023","journal-title":"Theranostics"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily--CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.6.2533","article-title":"CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells","volume":"183","author":"Krummel","year":"1996","journal-title":"J Exp Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.bj.2019.09.002","article-title":"Immune checkpoint inhibitors win the 2018 Nobel Prize","volume":"42","author":"Huang","year":"2019","journal-title":"BioMed J"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-24-0190","article-title":"Botensilimab, an Fc-enhanced anti-CTLA-4 antibody, is effective against tumors poorly responsive to conventional immunotherapy","volume":"14","author":"Chand","year":"2024","journal-title":"Cancer Discov"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.11.028","article-title":"Soluble CTLA-4 attenuates T cell activation and modulates anti-tumor immunity","volume":"32","author":"Kennedy","year":"2024","journal-title":"Mol Therapy: J Am Soc Gene Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.12891","article-title":"Immune therapeutics in the treatment of advanced gastric and esophageal cancer","volume":"38","author":"Park","year":"2018","journal-title":"Anticancer Res"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-19-2443","article-title":"Safety and efficacy of durvalumab and tremelimumab alone or in combination in patients with advanced gastric and gastroesophageal junction adenocarcinoma","volume":"26","author":"Kelly","year":"2020","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.76.6212","article-title":"CheckMate-032 study: Efficacy and safety of nivolumab and nivolumab plus ipilimumab in patients with metastatic esophagogastric cancer","volume":"36","author":"Janjigian","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.948647","article-title":"Recent progress and future perspectives of immunotherapy in advanced gastric cancer","volume":"13","author":"Jin","year":"2022","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/nejm198704093161501","article-title":"A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone","volume":"316","author":"Rosenberg","year":"1987","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1056\/nejm198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1084\/jem.174.1.139","article-title":"Use of a SCID mouse\/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity","volume":"174","author":"Schmidt-Wolf","year":"1991","journal-title":"J Exp Med"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.11778","article-title":"Efficacy of adoptive immune-cell therapy in patients with advanced gastric cancer: A retrospective study","volume":"37","author":"Takimoto","year":"2017","journal-title":"Anticancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1352805","article-title":"Adoptive T cell therapy for solid tumors: current landscape and future challenges","volume":"15","author":"Albarr\u00e1n","year":"2024","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v30.i4.286","article-title":"Revolutionizing gastric cancer treatment: The potential of immunotherapy","volume":"30","author":"Christodoulidis","year":"2024","journal-title":"World J Gastroenterol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050257","article-title":"Activated T cells and cytokine-induced CD3+CD56+ killer cells","volume":"74","author":"Schmidt-Wolf","year":"1997","journal-title":"Ann Hematol"},{"key":"B66","article-title":"Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial","volume":"8","author":"Kono","year":"2002","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S102909","article-title":"In vitro-activated tumor-specific T lymphocytes prolong the survival of patients with advanced gastric cancer: a retrospective cohort study","volume":"9","author":"Kuai","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.2217\/imt.16.10","article-title":"Efficacy of adoptive cellular therapy in patients with gastric cancer: a meta-analysis","volume":"8","author":"Shen","year":"2016","journal-title":"Immunotherapy"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Sci (New York NY)"},{"key":"B70","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s12935-024-03315-3","article-title":"Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors","volume":"24","author":"Chen","year":"2024","journal-title":"Cancer Cell Int"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.2147\/jir.S368138","article-title":"From anti-HER-2 to anti-HER-2-CAR-T cells: An evolutionary immunotherapy approach for gastric cancer","volume":"15","author":"Sun","year":"2022","journal-title":"J Inflammation Res"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v29.i40.5593","article-title":"Advances and key focus areas in gastric cancer immunotherapy: A comprehensive scientometric and clinical trial review (1999-2023)","volume":"29","author":"Li","year":"2023","journal-title":"World J Gastroenterol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152692","article-title":"Emerging therapeutic targets and future directions in advanced gastric cancer: A comprehensive review","volume":"16","author":"Ratti","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"PNAS"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720","article-title":"Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors","volume":"90","author":"Eshhar","year":"1993","journal-title":"PNAS"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.1.104","article-title":"Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain","volume":"172","author":"Finney","year":"2004","journal-title":"J Immunol (Baltimore Md: 1950)"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01740","article-title":"CAR T cells in solid tumors: Blueprints for building effective therapies","volume":"9","author":"Knochelmann","year":"2018","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2020.4982","article-title":"CAR T-cell therapy for gastric cancer: Potential and perspective (Review)","volume":"56","author":"Long","year":"2020","journal-title":"Int J Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.02.005","article-title":"FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma","volume":"32","author":"Sahin","year":"2021","journal-title":"Ann Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-19-1876","article-title":"Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer","volume":"9","author":"Hong","year":"2020","journal-title":"Transl Cancer Res"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djy134","article-title":"Claudin18.2-specific chimeric antigen receptor engineered T cells for the treatment of gastric cancer","volume":"111","author":"Jiang","year":"2019","journal-title":"J Natl Cancer Institute"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007927","article-title":"Metastatic gastric cancer target lesion complete response with Claudin18.2-CAR T cells","volume":"12","author":"Botta","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03037-z","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results","volume":"30","author":"Qi","year":"2024","journal-title":"Nat Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"B86","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41419-019-1711-1","article-title":"Modified CAR T cells\u00a0targeting\u00a0membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor","volume":"10","author":"Zhang","year":"2019","journal-title":"Cell Death Dis"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.02.013","article-title":"The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.660488","article-title":"Human hyaluronidase PH20 potentiates the antitumor activities of mesothelin-specific CAR-T cells against gastric cancer","volume":"12","author":"Zhao","year":"2021","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02689","article-title":"Impairment of NKG2D-mediated tumor immunity by TGF-\u03b2","volume":"10","author":"Lazarova","year":"2019","journal-title":"Front Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-018-3670-0","article-title":"Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment","volume":"82","author":"Tao","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s12275-024-00133-0","article-title":"Genetically engineered CLDN18.2 CAR-T cells expressing synthetic PD1\/CD28 fusion receptors produced using a lentiviral vector","volume":"62","author":"Lee","year":"2024","journal-title":"J Microbiol (Seoul Korea)"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118300","article-title":"CAR-T in solid tumors: Blazing a new trail through the brambles","volume":"260","author":"Guo","year":"2020","journal-title":"Life Sci"},{"key":"B93","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1038\/s41416-023-02332-9","article-title":"Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy","volume":"129","author":"Lorenzini","year":"2023","journal-title":"Br J Cancer"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2021.1901434","article-title":"Construction of\u00a0PD1\/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in\u00a0gastric cancer","volume":"10","author":"Chen","year":"2021","journal-title":"Oncoimmunology"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102113","article-title":"Collagen extracellular matrix promotes gastric cancer immune evasion by activating IL4I1-AHR signaling","volume":"49","author":"Zhang","year":"2024","journal-title":"Transl Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00071","article-title":"Scoring system for tumor-infiltrating lymphocytes and its prognostic value for gastric cancer","volume":"10","author":"Zhang","year":"2019","journal-title":"Front Immunol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ccell.2022.10.016","article-title":"Engineered T cell therapy for viral and non-viral epithelial cancers","volume":"41","author":"Norberg","year":"2023","journal-title":"Cancer Cell"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2010.30.5037","article-title":"Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer","volume":"29","author":"Mahmoud","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(09)70186-x","article-title":"CD3+ cells at the invasive margin of deeply invading (pT3-T4) colorectal cancer and risk of post-surgical metastasis: a longitudinal study","volume":"10","author":"Laghi","year":"2009","journal-title":"Lancet Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae136","article-title":"Lifileucel: FDA-approved T-cell therapy for melanoma","volume":"29","author":"Kwong","year":"2024","journal-title":"Oncologist"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2024.04.003","article-title":"Lifileucel: the first cellular therapy approved for solid tumours","volume":"10","author":"Julve","year":"2024","journal-title":"Trends Cancer"},{"key":"B102","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1093\/annonc\/mdv610","article-title":"Prognostic value of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric cancer","volume":"27","author":"Kang","year":"2016","journal-title":"Ann Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2024.102510","article-title":"Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a systematic review and meta-analysis","volume":"49","author":"Cao","year":"2025","journal-title":"Clinics Res Hepatol Gastroenterol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000011769","article-title":"Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a systematic review and meta-analysis","volume":"97","author":"Lee","year":"2018","journal-title":"Medicine"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-016-0631-3","article-title":"Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients","volume":"20","author":"Kawazoe","year":"2017","journal-title":"Gastric Cancer"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.molonc.2016.09.004","article-title":"Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer","volume":"10","author":"Dai","year":"2016","journal-title":"Mol Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1097\/pas.0000000000000848","article-title":"A novel numerical scoring system for melanoma tumor-infiltrating lymphocytes has better prognostic value than standard scoring","volume":"41","author":"Saldanha","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00908","article-title":"A novel method to generate and expand clinical-grade, genetically modified, tumor-infiltrating lymphocytes","volume":"8","author":"Forget","year":"2017","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-006001","article-title":"Generation of TGF\u03b2R2(-1) neoantigen-specific HLA-DR4-restricted T cell receptors for cancer therapy","volume":"11","author":"Plewa","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Sci (New York NY)"},{"key":"B111","article-title":"Expansion of CD3(+)CD8(+)PD1(+) T lymphocytes and TCR repertoire diversity predict clinical responses to adoptive cell therapy in advanced gastric cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Am J Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.05.013","article-title":"Cross-presentation of tumor antigens is ruled by synaptic transfer of vesicles among dendritic cell subsets","volume":"37","author":"Balan","year":"2020","journal-title":"Cancer Cell"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.2147\/ott.S150807","article-title":"The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody-drug conjugate for the treatment of newly diagnosed acute myeloid leukemia","volume":"11","author":"Egan","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00575","article-title":"Trastuzumab deruxtecan in anti-human epidermal growth factor receptor 2 treatment-naive patients with human epidermal growth factor receptor 2-low gastric or gastroesophageal junction adenocarcinoma: exploratory cohort results in a phase II trial","volume":"41","author":"Yamaguchi","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00262-024-03667-9","article-title":"Co-targeting CD47 and VEGF elicited potent anti-tumor effects in gastric cancer","volume":"73","author":"Zhang","year":"2024","journal-title":"Cancer Immunology Immunotherapy: CII"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-23-418","article-title":"Effect of ramucirumab plus paclitaxel in advanced gastric cancer according to the status of programmed cell death-ligand 1 (PD-L1) expression","volume":"14","author":"Choi","year":"2023","journal-title":"J Gastrointest Oncol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3892\/mco.2024.2715","article-title":"Efficacy of ramucirumab and subsequent nivolumab therapy in patients with advanced gastric cancer: a retrospective study","volume":"20","author":"Saito","year":"2024","journal-title":"Mol Clin Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1111\/ajco.13174","article-title":"Anti-angiogenic therapies for gastric cancer","volume":"15","author":"Hironaka","year":"2019","journal-title":"Asia-Pacific J Clin Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(14)70420-6","article-title":"Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial","volume":"15","author":"Wilke","year":"2014","journal-title":"Lancet Oncol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2015.63.5995","article-title":"Randomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction","volume":"34","author":"Li","year":"2016","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s00262-024-03806-2","article-title":"SAFFRON-104: a phase Ib\/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer\/gastroesophageal junction cancer","volume":"73","author":"Li","year":"2024","journal-title":"Cancer Immunology Immunotherapy: CII"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.06.007","article-title":"Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric\/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: an open-label, phase Ia\/b study (JVDJ)","volume":"137","author":"Bang","year":"2020","journal-title":"Eur J Cancer"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30458-9","article-title":"Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a\/b trial","volume":"20","author":"Herbst","year":"2019","journal-title":"Lancet Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-23-2328","article-title":"Low-dose apatinib optimizes the vascular normalization and enhances the antitumor effect of PD-1 inhibitor in gastric cancer","volume":"13","author":"Tao","year":"2024","journal-title":"Transl Cancer Res"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2016.10.003","article-title":"Therapeutics targeting FGF signaling network in human diseases","volume":"37","author":"Katoh","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01157-0","article-title":"Fibroblast growth factor receptors in cancer: genetic alterations, diagnostics, therapeutic targets and mechanisms of resistance","volume":"124","author":"Krook","year":"2021","journal-title":"Br J Cancer"},{"key":"B128","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","article-title":"FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (review)","volume":"38","author":"Katoh","year":"2016","journal-title":"Int J Mol Med"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00603-9","article-title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15071976","article-title":"The role of cMET in gastric cancer-a review of the literature","volume":"15","author":"Van Herpe","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1293728","article-title":"Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer","volume":"13","author":"Popiel","year":"2023","journal-title":"Front Oncol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"4074","DOI":"10.1038\/s41467-021-24367-3","article-title":"Structural basis of the activation of c-MET receptor","volume":"12","author":"Uchikawa","year":"2021","journal-title":"Nat Commun"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v16.i8.3397","article-title":"Research progress on the development of hepatocyte growth factor\/c-Met signaling pathway in gastric cancer: a review","volume":"16","author":"Wei","year":"2024","journal-title":"World J Gastrointest Oncol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1038\/s41419-023-06246-5","article-title":"A novel c-Met\/TRK inhibitor 1D228 efficiently inhibits tumor growth by targeting angiogenesis and tumor cell proliferation","volume":"14","author":"An","year":"2023","journal-title":"Cell Death Dis"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031769","article-title":"Comparison of tepotinib, paclitaxel, or ramucirumab efficacy according to the copy number or phosphorylation status of the MET gene: doublet treatment versus single agent treatment","volume":"25","author":"Sohn","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0038","article-title":"A randomized phase II study of FOLFOX with or without the MET inhibitor onartuzumab in advanced adenocarcinoma of the stomach and gastroesophageal junction","volume":"21","author":"Shah","year":"2016","journal-title":"Oncologist"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-049575","article-title":"Comparative efficacy and safety of anti-HGF\/MET pathway agents plus chemotherapy versus chemotherapy alone as first-line treatment in advanced gastric cancer: a protocol for a systematic review and meta-analysis","volume":"11","author":"Jiang","year":"2021","journal-title":"BMJ Open"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.5580","article-title":"Effect of fluorouracil, leucovorin, and oxaliplatin with or without onartuzumab in HER2-negative, MET-positive gastroesophageal adenocarcinoma: the METGastric randomized clinical trial","volume":"3","author":"Shah","year":"2017","journal-title":"JAMA Oncol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ejca.2019.04.020","article-title":"FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial","volume":"115","author":"Malka","year":"2019","journal-title":"Eur J Cancer"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-18-4010","article-title":"A phase Ib\/II study of ramucirumab in combination with emibetuzumab in patients with advanced cancer","volume":"25","author":"Harding","year":"2019","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3445-z","article-title":"A non-randomized, open-label, single-arm, phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer","volume":"80","author":"Sakai","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-020-00940-3","article-title":"Tivantinib inhibits the VEGF signaling pathway and induces apoptosis in gastric cancer cells with c-MET or VEGFA amplification","volume":"38","author":"Kim","year":"2020","journal-title":"Invest New Drugs"},{"key":"B143","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10120-024-01478-6","article-title":"Elucidating molecular mechanisms and therapeutic synergy: irreversible HER2-TKI plus T-Dxd for enhanced anti-HER2 treatment of gastric cancer","volume":"27","author":"Liu","year":"2024","journal-title":"Gastric Cancer"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-010041","article-title":"Multiomics reveals tumor microenvironment remodeling in locally advanced gastric and gastroesophageal junction cancer following neoadjuvant immunotherapy and chemotherapy","volume":"12","author":"Ji","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34296","article-title":"First-line nivolumab plus chemotherapy vs chemotherapy in patients with advanced gastric, gastroesophageal junction and esophageal adenocarcinoma: CheckMate 649 Chinese subgroup analysis","volume":"152","author":"Liu","year":"2023","journal-title":"Int J Cancer"},{"key":"B146","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/s41392-025-02193-z","article-title":"PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial","volume":"10","author":"Wang","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1448485","article-title":"An exploratory clinical study of \u03b2-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma","volume":"15","author":"Chu","year":"2024","journal-title":"Front Immunol"},{"key":"B148","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/oncolo\/oyae005","article-title":"Apatinib plus toripalimab (anti-PD1 therapy) as second-line therapy in patients with advanced gastric or esophagogastric junction cancer: results from a randomized, open-label phase II study","volume":"29","author":"Wei","year":"2024","journal-title":"Oncologist"},{"key":"B149","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/s12885-023-10661-4","article-title":"Sintilimab plus apatinib and chemotherapy as second-\/third-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: a prospective, single-arm, phase II trial","volume":"23","author":"Zhang","year":"2023","journal-title":"BMC Cancer"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21705","article-title":"Antibody-drug conjugates: smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA: A Cancer J For Clin"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.62347\/qcdr9612","article-title":"HER2-targeted ADC DX126\u2013262 combined with chemotherapy demonstrates superior antitumor efficacy in HER2-positive gastric cancer","volume":"14","author":"Cai","year":"2024","journal-title":"Am J Cancer Res"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2024.101086","article-title":"Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement","volume":"75","author":"Jiang","year":"2024","journal-title":"Drug Resistance Updates: Rev Commentaries Antimicrobial Anticancer Chemotherapy"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1291117","article-title":"Research progress on the immune microenvironment and immunotherapy in gastric cancer","volume":"14","author":"Mou","year":"2023","journal-title":"Front Immunol"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.2228","article-title":"Efficacy of ipilimumab vs FOLFOX in combination with nivolumab and trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma: The AIO INTEGA randomized clinical trial","volume":"8","author":"Stein","year":"2022","journal-title":"JAMA Oncol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-021-01168-7","article-title":"Phase I study of the recombinant humanized anti-HER2 monoclonal antibody-MMAE conjugate RC48-ADC in patients with HER2-positive advanced solid tumors","volume":"24","author":"Xu","year":"2021","journal-title":"Gastric Cancer"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12214","article-title":"Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study","volume":"41","author":"Peng","year":"2021","journal-title":"Cancer Commun (London England)"},{"key":"B157","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/s1470-2045(16)30631-3","article-title":"Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study","volume":"18","author":"Luen","year":"2017","journal-title":"Lancet Oncol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2021.1936494","article-title":"Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics","volume":"21","author":"Saini","year":"2021","journal-title":"Expert Opin Biol Ther"},{"key":"B159","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1186\/s12885-023-11735-z","article-title":"Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: a multicenter real-world study","volume":"23","author":"Nie","year":"2023","journal-title":"BMC Cancer"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12122746","article-title":"Coley's toxin to first approved therapeutic vaccine-a brief historical account in the progression of immunobiology-based cancer treatment","volume":"12","author":"Devaraja","year":"2024","journal-title":"Biomedicines"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9060647","article-title":"Vaccines in gastrointestinal Malignancies: From prevention to treatment","volume":"9","author":"Chudasama","year":"2021","journal-title":"Vaccines"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10588","article-title":"Cancer vaccines in the clinic","volume":"9","author":"Janes","year":"2024","journal-title":"Bioengineering Trans Med"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22020779","article-title":"Cancer vaccines, treatment of the future: With emphasis on HER2-positive breast cancer","volume":"22","author":"Pallerla","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-12-803678-5.00167-3","article-title":"Dendritic cells pulsed with HER-2\/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer","volume":"8","author":"Kono","year":"2002","journal-title":"Clin Cancer Research: Off J Am Assoc For Cancer Res"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153322","article-title":"Immunotherapy of gastric cancer: Past, future perspective and challenges","volume":"218","author":"Xie","year":"2021","journal-title":"Pathol Res Pract"},{"key":"B166","article-title":"Therapeutic vaccines for gastrointestinal cancers","volume":"7","author":"Rahma","year":"2011","journal-title":"Gastroenterol Hepatol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1177\/15330338221150555","article-title":"Research progress of immunotherapy for gastric cancer","volume":"22","author":"Zhang","year":"2023","journal-title":"Technol Cancer Res Treat"},{"key":"B168","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol Cancer"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2012.03.020","article-title":"Doxil\u00ae--the first FDA-approved nano-drug: lessons learned","volume":"160","author":"Barenholz","year":"2012","journal-title":"J Controlled Release: Off J Controlled Release Soc"},{"key":"B170","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1186\/s12951-023-02203-8","article-title":"TH-302-loaded nanodrug reshapes the hypoxic tumour microenvironment and enhances PD-1 blockade efficacy in gastric cancer","volume":"21","author":"Wang","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"B171","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1186\/s12967-024-05498-9","article-title":"CircRHBDD1 promotes immune escape via IGF2BP2\/PD-L1 signaling and acts as a nanotherapeutic target in gastric cancer","volume":"22","author":"Li","year":"2024","journal-title":"J Transl Med"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1142\/s1088424608000273","article-title":"Adventures in photodynamic therapy: 1976-2008","volume":"12","author":"Kessel","year":"2008","journal-title":"J Porphyr Phthalocyanines"},{"key":"B173","first-page":"48","article-title":"Hyperthermia in cancer research. Historical development, current status of research, future perspectives and differentiation from alternative medical procedures","volume":"41","author":"Issels","year":"1989","journal-title":"Versicherungsmedizin"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202307870","article-title":"Enhanced photodynamic therapy synergizing with inhibition of tumor neutrophil ferroptosis boosts anti-PD-1 therapy of gastric cancer","volume":"11","author":"Zhu","year":"2024","journal-title":"Advanced Sci (Weinheim Baden-Wurttemberg Germany)"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241266156","article-title":"Research progress and future directions of immune checkpoint inhibitor combination therapy in advanced gastric cancer","volume":"16","author":"He","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2023.148111","article-title":"Hyperthermia inhibits the progression of gastric cancer by downregulating PLEK2\/PD-L1 and possibly participates in immunomodulation","volume":"898","author":"Li","year":"2024","journal-title":"Gene"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.2134","article-title":"Chinese medicines and natural medicine as immunotherapeutic agents for gastric cancer: Recent advances","volume":"7","author":"Zhang","year":"2024","journal-title":"Cancer Rep (Hoboken NJ)"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1581885","article-title":"Bibliometric analysis of traditional Chinese medicine in cancer treatment via immune system modulation (2015-2025)","volume":"16","author":"Lei","year":"2025","journal-title":"Front Immunol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2019.104623","article-title":"Modified Bu-zhong-yi-qi decoction synergies with 5 fluorouracile to inhibits gastric cancer progress via PD-1\/PD-L1-dependent T cell immunization","volume":"152","author":"Xu","year":"2020","journal-title":"Pharmacol Res"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154229","article-title":"Effect of modified Jianpi Yangzheng on regulating content of PKM2 in gastric cancer cells-derived exosomes","volume":"103","author":"Wu","year":"2022","journal-title":"Phytomedicine: Int J Phytotherapy Phytopharmacology"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1159829","article-title":"Jianpi Yangzheng Xiaozheng decoction alleviates gastric cancer progression via suppressing exosomal PD-L1","volume":"14","author":"Chen","year":"2023","journal-title":"Front Pharmacol"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01654-2","article-title":"Helicobacter pylori and gastric cancer: mechanisms and new perspectives","volume":"18","author":"Duan","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-323392","article-title":"Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies","volume":"71","author":"Oster","year":"2022","journal-title":"Gut"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-024-03034-7","article-title":"Unveiling the gastric microbiota: implications for gastric carcinogenesis, immune responses, and clinical prospects","volume":"43","author":"Liu","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12370","article-title":"Dr. Eberhard Trams-the man who coined the name \"exosomes\"-a prescient but largely forgotten pioneer","volume":"12","author":"MacDonald","year":"2023","journal-title":"J Extracell Vesicles"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602360","article-title":"Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system","volume":"92","author":"Whiteside","year":"2005","journal-title":"Br J Cancer"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.15171\/bi.2015.22","article-title":"A prospective highlight on exosomal nanoshuttles and cancer immunotherapy and vaccination","volume":"5","author":"Rafi","year":"2015","journal-title":"BioImpacts: BI"},{"key":"B188","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s12943-022-01557-1","article-title":"LSD1 deletion decreases exosomal PD-L1 and restores T-cell response in gastric cancer","volume":"21","author":"Shen","year":"2022","journal-title":"Mol Cancer"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03355-6","article-title":"A nanotherapeutic system for gastric cancer suppression by synergistic chemotherapy and immunotherapy based on iPSCs and DCs exosomes","volume":"72","author":"Li","year":"2023","journal-title":"Cancer Immunology Immunotherapy: CII"},{"key":"B190","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41419-024-06758-8","article-title":"Extracellular vesicles mediated gastric cancer immune response: tumor cell death or immune escape","volume":"15","author":"Yang","year":"2024","journal-title":"Cell Death Dis"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1415148","article-title":"HIGD1B, as a novel prognostic biomarker, is involved in regulating the tumor microenvironment and immune cell infiltration; its overexpression leads to poor prognosis in gastric cancer patients","volume":"15","author":"Wang","year":"2024","journal-title":"Front Immunol"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2021.188615","article-title":"Advances in clinical immunotherapy for gastric cancer","volume":"1876","author":"Li","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.8169","article-title":"PD-L1 is an independent prognostic predictor in gastric cancer of Western patients","volume":"7","author":"B\u00f6ger","year":"2016","journal-title":"Oncotarget"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12072636","article-title":"Updated immunotherapy for gastric cancer","volume":"12","author":"Narita","year":"2023","journal-title":"J Clin Med"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2020.100036","article-title":"Predictive role of microsatellite instability for PD-1 blockade in patients with advanced gastric cancer: a meta-analysis of randomized clinical trials","volume":"6","author":"Pietrantonio","year":"2021","journal-title":"ESMO Open"},{"key":"B196","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12943-020-01274-7","article-title":"The predicting role of circulating tumor DNA landscape in gastric cancer patients treated with immune checkpoint inhibitors","volume":"19","author":"Jin","year":"2020","journal-title":"Mol Cancer"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.923477","article-title":"Effects of helicobacter pylori on tumor microenvironment and immunotherapy responses","volume":"13","author":"Deng","year":"2022","journal-title":"Front Immunol"},{"key":"B198","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13045-022-01273-9","article-title":"Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies","volume":"15","author":"Lu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B199","doi-asserted-by":"publisher","first-page":"7648","DOI":"10.1038\/s41598-024-57714-7","article-title":"Integrated analysis of single-cell and bulk RNA-sequencing reveals a novel signature based on NK cell marker genes to predict prognosis and immunotherapy response in gastric cancer","volume":"14","author":"Sun","year":"2024","journal-title":"Sci Rep"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-024-08365-1","article-title":"Integrated analysis construct a tumor-associated macrophage novel signature with promising implications in predicting the prognosis and immunotherapeutic response of gastric cancer patients","volume":"69","author":"Xin","year":"2024","journal-title":"Dig Dis Sci"},{"key":"B201","doi-asserted-by":"publisher","first-page":"4524","DOI":"10.1038\/s41598-024-54273-9","article-title":"Development of a CD8+\u2009T cell associated signature for predicting the prognosis and immunological characteristics of gastric cancer by integrating single-cell and bulk RNA-sequencing","volume":"14","author":"Li","year":"2024","journal-title":"Sci Rep"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000037439","article-title":"Establishment of Golgi apparatus-related genes signature to predict the prognosis and immunotherapy response in gastric cancer patients","volume":"103","author":"Liu","year":"2024","journal-title":"Medicine"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v16.i3.919","article-title":"Construction of an immune-related gene signature for overall survival prediction and immune infiltration in gastric cancer","volume":"16","author":"Ma","year":"2024","journal-title":"World J Gastrointest Oncol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v16.i7.3097","article-title":"Glycolysis-related five-gene signature correlates with prognosis and immune infiltration in gastric cancer","volume":"16","author":"Meng","year":"2024","journal-title":"World J Gastrointest Oncol"},{"key":"B205","doi-asserted-by":"publisher","first-page":"89","DOI":"10.18632\/aging.205341","article-title":"Characterization of m6A methylation modifications in gastric cancer","volume":"16","author":"Yin","year":"2024","journal-title":"Aging"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12030491","article-title":"The Gastric Cancer Immune Prognostic Score (GCIPS) shows potential in predicting an unfavorable prognosis for gastric cancer patients undergoing immune checkpoint inhibitor treatment","volume":"12","author":"Zuo","year":"2024","journal-title":"Biomedicines"},{"key":"B207","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1186\/s12885-024-12174-0","article-title":"A radiomics signature derived from CT imaging to predict MSI status and immunotherapy outcomes in gastric cancer: a multi-cohort study","volume":"24","author":"Zhan","year":"2024","journal-title":"BMC Cancer"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1172\/jci175834","article-title":"Comprehensive assessment of immune context and immunotherapy response via noninvasive imaging in gastric cancer","volume":"134","author":"Sun","year":"2024","journal-title":"J Clin Invest"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1375013","article-title":"Gastric cancer fibroblasts affect the effect of immunotherapy and patient prognosis by inducing micro-vascular production","volume":"15","author":"Xia","year":"2024","journal-title":"Front Immunol"},{"key":"B210","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1007\/s00262-024-03684-8","article-title":"New genetic insights into immunotherapy outcomes in gastric cancer via single-cell RNA sequencing and random forest model","volume":"73","author":"Yu","year":"2024","journal-title":"Cancer Immunology Immunotherapy: CII"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-026-08505-7","article-title":"Cancer-associated fibroblasts promote osimertinib resistance in non-small cell lung cancer cells via METTL1-mediated NET1 m(7)G modification","volume":"17","author":"Qian","year":"2026","journal-title":"Cell Death Dis"},{"key":"B212","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12967-024-04859-8","article-title":"A novel biomarker associated with EBV infection improves response prediction of immunotherapy in gastric cancer","volume":"22","author":"Li","year":"2024","journal-title":"J Transl Med"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2019.144034","article-title":"Histone chaperone CHAF1A impacts the outcome of fluoropyrimidines-based adjuvant therapy in gastric cancer by regulating the expression of thymidylate synthetase","volume":"716","author":"Wang","year":"2019","journal-title":"Gene"},{"key":"B214","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00262-024-03716-3","article-title":"GGT5: a potential immunotherapy response inhibitor in gastric cancer by modulating GSH metabolism and sustaining memory CD8+ T cell infiltration","volume":"73","author":"Zhao","year":"2024","journal-title":"Cancer Immunology Immunotherapy: CII"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.18632\/aging.103429","article-title":"Cancer-associated fibroblasts-derived gamma-glutamyltransferase 5 promotes tumor growth and drug resistance in lung adenocarcinoma","volume":"12","author":"Wei","year":"2020","journal-title":"Aging"},{"key":"B216","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12885-024-11999-z","article-title":"Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC Cancer"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.6.7.4253","article-title":"Possible involvement of persistent activity of the mammalian target of rapamycin pathway in the cisplatin resistance of AFP-producing gastric cancer cells","volume":"6","author":"Kamata","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.18632\/aging.205694","article-title":"KIF3C: an emerging biomarker with prognostic and immune implications across pan-cancer types and its experiment validation in gastric cancer","volume":"16","author":"Zhong","year":"2024","journal-title":"Aging"},{"key":"B219","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13046-024-02972-6","article-title":"MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis","volume":"43","author":"Wang","year":"2024","journal-title":"J Exp Clin Cancer Res"},{"key":"B220","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/s41419-024-07155-x","article-title":"VASH2 enhances KIF3C-mediated EGFR-endosomal recycling to promote aggression and chemoresistance of lung squamous cell carcinoma by increasing tubulin detyrosination","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death Dis"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.2147\/ijgm.S444443","article-title":"NFS1 as a candidate prognostic biomarker for gastric cancer correlated with immune infiltrates","volume":"17","author":"Jiang","year":"2024","journal-title":"Int J Gen Med"},{"key":"B222","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41392-022-00889-0","article-title":"Phosphorylated NFS1 weakens oxaliplatin-based chemosensitivity of colorectal cancer by preventing PANoptosis","volume":"7","author":"Lin","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1324959","article-title":"Identification and characterization of CLEC11A and its derived immune signature in gastric cancer","volume":"15","author":"Zheng","year":"2024","journal-title":"Front Immunol"},{"key":"B224","doi-asserted-by":"publisher","first-page":"63","DOI":"10.21037\/jgo-23-984","article-title":"The prognostic value and potential immunotherapeutic efficacy of ACVR1 in treating gastric cancer","volume":"15","author":"Zhang","year":"2024","journal-title":"J Gastrointest Oncol"},{"key":"B225","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41375-023-02086-6","article-title":"TP-0184 inhibits FLT3\/ACVR1 to overcome FLT3 inhibitor resistance and hinder AML growth synergistically with venetoclax","volume":"38","author":"Tyagi","year":"2024","journal-title":"Leukemia"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1097\/md.0000000000037863","article-title":"Geriatric nutritional risk index predicts the prognosis of gastric cancer patients treated with immune checkpoint inhibitors","volume":"103","author":"Liu","year":"2024","journal-title":"Medicine"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1367990","article-title":"Prognostic relevance of platelet lymphocyte ratio (PLR) in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Hou","year":"2024","journal-title":"Front Oncol"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1070019","article-title":"Prognostic value of neutrophil to lymphocyte ratio in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24437","article-title":"AFF3 is a novel prognostic biomarker and a potential target for immunotherapy in gastric cancer","volume":"36","author":"Zeng","year":"2022","journal-title":"J Clin Lab Anal"},{"key":"B230","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1186\/s13046-018-0928-7","article-title":"AFF3 upregulation mediates tamoxifen resistance in breast cancers","volume":"37","author":"Shi","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.808041","article-title":"TGF\u03b22 is a prognostic biomarker for gastric cancer and is associated with methylation and immunotherapy responses","volume":"13","author":"Han","year":"2022","journal-title":"Front Genet"},{"key":"B232","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s12967-023-04063-0","article-title":"Mesenchymal stromal cells promote the drug resistance of gastrointestinal stromal tumors by activating the PI3K-AKT pathway via TGF-\u03b22","volume":"21","author":"Zhao","year":"2023","journal-title":"J Transl Med"},{"key":"B233","doi-asserted-by":"publisher","first-page":"8400","DOI":"10.1038\/s41598-022-12531-8","article-title":"Identification of AKIRIN2 as a potential biomarker and correlation with immunotherapy in gastric adenocarcinoma by integrated bioinformatics analysis","volume":"12","author":"Sun","year":"2022","journal-title":"Sci Rep"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1080\/10245332.2018.1488795","article-title":"Expression analysis of Akirin-2, NF\u03baB-p65 and \u03b2-catenin proteins in imatinib resistance of chronic myeloid leukemia","volume":"23","author":"Karabay","year":"2018","journal-title":"Hematol (Amsterdam Netherlands)"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-22-115","article-title":"Bioinformatics analysis of the prognostic and immunotherapeutic significance of NPRL2 in stomach adenocarcinoma","volume":"13","author":"Pi","year":"2022","journal-title":"J Gastrointest Oncol"},{"key":"B236","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.21037\/atm-21-3376","article-title":"Blood alkaline phosphatase predicts prognosis of patients with advanced HER2-negative gastric cancer receiving immunotherapy","volume":"9","author":"Hu","year":"2021","journal-title":"Ann Transl Med"},{"key":"B237","doi-asserted-by":"publisher","first-page":"31634","DOI":"10.1038\/s41598-025-17563-4","article-title":"Evaluation of serum alkaline phosphatase and lactate dehydrogenase as predictive biomarkers for the prognosis of male breast cancer","volume":"15","author":"Kong","year":"2025","journal-title":"Sci Rep"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-020-01120-1","article-title":"Expression of the immune checkpoint molecule V-set immunoglobulin domain-containing 4 is associated with poor prognosis in patients with advanced gastric cancer","volume":"24","author":"Kim","year":"2021","journal-title":"Gastric Cancer"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113105","article-title":"VSIG4 induces the immunosuppressive microenvironment by promoting the infiltration of M2 macrophage and Tregs in clear cell renal cell carcinoma","volume":"142","author":"Zheng","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B240","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1186\/s12885-023-11620-9","article-title":"Impact of low serum iron on treatment outcome of PD-1 inhibitors in advanced gastric cancer","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Cancer"},{"key":"B241","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/s41598-023-28234-7","article-title":"Data mining combines bioinformatics discover immunoinfiltration-related gene SERPINE1 as a biomarker for diagnosis and prognosis of stomach adenocarcinoma","volume":"13","author":"Zhai","year":"2023","journal-title":"Sci Rep"},{"key":"B242","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s10565-025-10050-6","article-title":"NFATC2\/SERPINE1\/JAK3\/STAT3 signaling feedback loop in gastric cancer: immune evasion and anti-PD-1 resistance","volume":"41","author":"Yang","year":"2025","journal-title":"Cell Biol Toxicol"},{"key":"B243","doi-asserted-by":"publisher","first-page":"9360","DOI":"10.1038\/s41598-023-36586-3","article-title":"High expression of GPR176 predicts poor prognosis of gastric cancer patients and promotes the proliferation, migration, and invasion of gastric cancer cells","volume":"13","author":"Zhang","year":"2023","journal-title":"Sci Rep"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-05256-2","article-title":"The promoting effects of GPR176 expression on proliferation, chemoresistance, lipogenesis and invasion of oesophageal cancer","volume":"149","author":"Yun","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.24976\/Discov.Med.202335179.115","article-title":"Autophagy-related gene CXCR4 is a potential predictor of prognosis and immunotherapy response for gastric cancer","volume":"35","author":"Zhao","year":"2023","journal-title":"Discov Med"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2021.153532","article-title":"Retinoblastoma tumor suppressor gene 1 enhances 5-fluorouracil chemosensitivity through SDF-1\/CXCR4 axis by regulating autophagy in gastric cancer","volume":"224","author":"Tang","year":"2021","journal-title":"Pathol Res Pract"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241411870","article-title":"SKAP1 is a novel biomarker and therapeutic target for gastric cancer: evidence from expression, functional, and bioinformatic analyses","volume":"24","author":"Zhu","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1049\/syb2.70038","article-title":"Integrative analysis of TLS-associated gene signatures, immune infiltration and drug sensitivity in pancreatic cancer","volume":"19","author":"Gao","year":"2025","journal-title":"IET Syst Biol"},{"key":"B249","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s12920-023-01659-9","article-title":"COL5A2 is a prognostic-related biomarker and correlated with immune infiltrates in gastric cancer based on transcriptomics and single-cell RNA sequencing","volume":"16","author":"Chen","year":"2023","journal-title":"BMC Med Genomics"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.7150\/ijms.85253","article-title":"Prognostic value and immunological roles of GPX3 in gastric cancer","volume":"20","author":"He","year":"2023","journal-title":"Int J Med Sci"},{"key":"B251","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1186\/s12885-023-11308-0","article-title":"GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Cancer"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.29358","article-title":"Guanylate-binding protein-2 inhibits colorectal cancer cell growth and increases the sensitivity to paclitaxel of paclitaxel-resistant colorectal cancer cells by interfering Wnt signaling","volume":"121","author":"Wang","year":"2020","journal-title":"J Cell Biochem"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5042","article-title":"ITGB1 as a prognostic biomarker correlated with immune suppression in gastric cancer","volume":"12","author":"Gu","year":"2023","journal-title":"Cancer Med"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.18632\/aging.203355","article-title":"Type I collagen promotes tumor progression of integrin \u03b21 positive gastric cancer through a BCL9L\/\u03b2-catenin signaling pathway","volume":"13","author":"Lv","year":"2021","journal-title":"Aging"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03240-2","article-title":"The tissue-resident marker CD103 on peripheral blood T cells predicts responses to anti-PD-1 therapy in gastric cancer","volume":"72","author":"Nose","year":"2023","journal-title":"Cancer Immunology Immunotherapy: CII"},{"key":"B256","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s43018-021-00221-9","article-title":"Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma","volume":"2","author":"Haas","year":"2021","journal-title":"Nat Cancer"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-0810-1","article-title":"OX40 and LAG3 are associated with better prognosis in advanced gastric cancer patients treated with anti-programmed death-1 antibody","volume":"122","author":"Ohmura","year":"2020","journal-title":"Br J Cancer"},{"key":"B258","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1158\/2159-8290.Cd-21-0888","article-title":"Early tumor-immune microenvironmental remodeling and response to first-line fluoropyrimidine and platinum chemotherapy in advanced gastric cancer","volume":"12","author":"Kim","year":"2022","journal-title":"Cancer Discov"},{"key":"B259","article-title":"OX40 as a novel target for the reversal of immune escape in colorectal cancer","volume":"13","author":"Yan","year":"2021","journal-title":"Am J Trans Res"},{"key":"B260","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1186\/s12876-024-03447-w","article-title":"Integrin \u03b25, a noninvasive diagnostic biomarker, is associated with unfavorable prognosis and immunotherapy efficacy in gastric cancer","volume":"24","author":"Cheng","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106789","article-title":"Upregulation of CSNK1A1 induced by ITGB5 confers to hepatocellular carcinoma resistance to sorafenib in vivo by disrupting the EPS15\/EGFR complex","volume":"192","author":"Gu","year":"2023","journal-title":"Pharmacol Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1742723\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T05:44:01Z","timestamp":1778564641000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1742723\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,12]]},"references-count":261,"alternative-id":["10.3389\/fimmu.2026.1742723"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1742723","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,12]]},"article-number":"1742723"}}